This is a preview of subscription content, log in via an institution to check access.
Notes
The studies were funded by Pfizer.
References
Floros L, et al. Estimating the Cost-Effectiveness of Isavuconazole for the Treatment of Patients with Possible Invasive Aspergillosis in the United Kingdom. 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PIN59, 10 Nov 2018. Available from: URL: https://tools.ispor.org/ScientificPresentationsDatabase/Presentation/88338?pdfid=56737
Hajickova B, et al. Cost-Effectiveness Analysis of Isavuconazole for the Treatment of Invasive Aspergillosis in the Czech Republic. 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PIN68, 10 Nov 2018. Available from: URL: https://tools.ispor.org/ScientificPresentationsDatabase/Presentation/86116?pdfid=56801
Rights and permissions
About this article
Cite this article
Isavuconazole good value for money in invasive aspergillosis. PharmacoEcon Outcomes News 817, 19 (2018). https://doi.org/10.1007/s40274-018-5476-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-018-5476-z